Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.

Area of Science:

• Respiratory Medicine
• Clinical Trials
• Pharmacology

Background:

• Chronic bronchitis and COPD patients experience recurrent exacerbations, increasing personal and healthcare costs.
• Mucolytics are used to manage these conditions, but their effectiveness varies globally.
• Reducing exacerbation frequency is a key therapeutic goal.

Purpose of the Study:

• To evaluate if mucolytic treatment reduces exacerbation frequency and disability days in chronic bronchitis or COPD.
• To assess mucolytics' impact on lung function, quality of life, and adverse effects.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) of oral mucolytics versus placebo.
• Searched Cochrane Airways Group Specialised Register up to July 2012.
• Included 30 RCTs with 7436 participants; excluded asthma and cystic fibrosis studies.

Main Results:

• Mucolytics showed a statistically significant reduction in exacerbations (OR 1.84) and disability days (MD -0.48).
• Number needed to treat (NNTB) was 7 to prevent one exacerbation over 10 months.
• No significant improvement in lung function or quality of life; no increased adverse effects or mortality.

Conclusions:

• Mucolytics may offer a modest reduction in acute exacerbations for chronic bronchitis/COPD patients.
• Observed benefits in early trials were larger than in recent studies, potentially due to bias.
• Little to no effect on overall quality of life was observed.